brands of semaglutide Buyer Beware: Off-brand Ozempic, Zepbound and Other Weight Loss Products Carry Undisclosed Risks Is Semaglutide the Same as

Key Findings: Large human studies across multiple countries have not found increased thyroid cancer rates in GLP-1 users The FDA warning applies to medullary thyroid carcinoma (MTC)only 3-4% of all thyroid cancers The warning exists because rodents developed C-cell tumors, but humans and rodents differ biologically Some studies show associations, but these are explained by detection bias (more monitoring = finding pre-existing nodules) The Clayman Thyroid Center (2,000+ thyroid cancer patients/year) has not seen an MTC pattern linked to GLP-1 use (or for that matter any other thyroid malignancy) Clinical Recommendations: Patients with MTC history or MEN2 should not take GLP-1 receptor agonists Patients with common thyroid cancers (papillary, follicular, Hrthle cell) should not assume GLP-1 caused them or will have an effect upon them Decisions should be individualized, weighing metabolic benefits against theoretical concerns GLP-1 therapy does not require additional thyroid monitoring Quick Reference for Clinicians Understanding the Question What Medications Are We Discussing

As with any emerging treatment, we know our patients have questions

this effect is not dependent on the activation of G-protein-coupled melatonin receptors but on nuclear factor-kappa B (NF-B) 77

These symptoms could indicate a thyroid imbalance, nutritional deficiency from rapid weight loss, or an unrelated gynecological issuenone of which are caused by semaglutide but may need separate evaluation